Show simple item record

An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC).

dc.contributor.authorDomchek, S
dc.contributor.authorPostel-Vinay, S
dc.contributor.authorBang, Y
dc.contributor.authorPark, Y
dc.contributor.authorAlexandre, J
dc.contributor.authorDelord, J
dc.contributor.authorItaliano, A
dc.contributor.authorYou, B
dc.contributor.authorBastian, S
dc.contributor.authorKrebs, Matthew G
dc.contributor.authorWang, D
dc.contributor.authorWaqar, S
dc.contributor.authorAngell, H
dc.contributor.authorLearoyd, M
dc.contributor.authorChang, S
dc.contributor.authorGresty, C
dc.contributor.authorHerbolsheimer, P
dc.contributor.authorKaufman, B
dc.date.accessioned2018-04-30T21:10:47Z
dc.date.available2018-04-30T21:10:47Z
dc.date.issued2018-02-14
dc.identifier.citationAn open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC). 2018, 78(4 Suppl): PD6-11 Cancer Resen
dc.identifier.issn0008-5472
dc.identifier.issn1538-7445
dc.identifier.doi10.1158/1538-7445.SABCS17-PD6-11
dc.identifier.urihttp://hdl.handle.net/10541/620934
dc.language.isoenen
dc.relation.urlhttp://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.SABCS17-PD6-11en
dc.rightsArchived with thanks to Cancer Researchen
dc.titleAn open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC).en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentCancer Research Basser Center, University of Pennsylvania, Philadelphia, PAen
dc.identifier.journalCancer Researchen


This item appears in the following Collection(s)

Show simple item record